Solitary pulmonary nodule and incidental lung findings

01Purpose and principlesWhat the assessment is for and the core concepts behind it.

Most incidentally detected small pulmonary nodules are benign, but the pathway must identify the minority representing early cancer without exposing everyone to repeated radiation, invasive biopsy or prolonged uncertainty. The report should specify number, lobe, dimensions or volume, attenuation, morphology and comparison. Clinical context matters: previous malignancy, immune status, active infection and a known extrathoracic cancer may place the patient outside a routine incidental-nodule algorithm. A named clinician or service must own both the result and communication of the plan.

For solid nodules, BTS guidance combines size and morphology with Brock risk, interval volumetry and, where technically useful, PET-CT followed by Herder reassessment. Subsolid nodules require confirmation of persistence and attention to any solid component because slow growth does not mean harmless biology. Biopsy route depends on location, bronchus sign, pneumothorax risk and whether mediastinal staging is also needed. If treatment would be pursued despite an unsafe or non-diagnostic biopsy, multidisciplinary discussion may support definitive local treatment based on a sufficiently high clinical probability, after explaining uncertainty.

Key points

A pulmonary nodule is an imaging description, not a diagnosis; first confirm that the apparent opacity is intrapulmonary and characterise it on thin-section CT.
Retrieve all prior chest imaging before ordering serial scans because long-term stability, true growth or a previously overlooked lesion can change the pathway immediately.
Risk assessment integrates age, smoking, cancer history, nodule size, morphology and location; use the BTS-endorsed Brock model in its intended population rather than intuition alone.
Volumetry is preferred when available because small diameter changes are difficult to measure reproducibly; compare technique and calculate volume-doubling behaviour through the formal pathway.
Solid, part-solid and pure ground-glass nodules have different natural histories and surveillance logic; do not apply one schedule to all three.
PET-CT refines risk only when the lesion is large enough for reliable characterisation; inflammation can be avid and indolent or small malignancies can be falsely negative.
The decision after risk stratification is shared among discharge, CT surveillance, biopsy, resection or non-surgical treatment, accounting for fitness and whether tissue would change care.
An incidental scan may also reveal emphysema, interstitial abnormality, pleural disease, infection, airway obstruction or coronary calcification; each needs explicit triage rather than a generic repeat scan.

02Indications, selection and cautionsWhen it is useful, when urgency changes and important limitations.

Higher-risk morphology

Spiculation, upper-lobe position, increasing size, pleural indentation or a growing solid component raises concern, but no isolated visual feature proves malignancy.

Clearly benign patterns

Typical benign calcification or macroscopic fat in a well-characterised lesion can support discharge, provided the radiological pattern is genuinely diagnostic rather than partly calcified uncertainty.

Subsolid phenotype

Pure ground-glass and part-solid nodules often evolve slowly; persistence, total size and growth of the solid portion are more informative than brief apparent stability.

Multiple nodules

Assess the most suspicious lesion while considering infection, inflammatory disease and metastases; multiple nodules are not automatically metastatic and may still follow a nodule pathway.

Clinical context exception

Active cancer, marked immunosuppression, fever or septic embolic features may require disease-specific or urgent assessment instead of standard incidental surveillance.

Incidental non-nodule signal

Fibrotic interstitial change, a central obstructing lesion, pleural nodularity, significant bronchiectasis or an acute infiltrate may be more important than the index nodule and needs a separate action.

Red flags requiring action

Haemoptysis, a central obstructing lesion, lobar collapse, suspicious lymphadenopathy or a rapidly enlarging mass should enter an urgent lung-cancer pathway rather than routine nodule surveillance.
A new nodule with sepsis, immunosuppression, cavitation or possible embolic infection needs prompt clinical assessment; delaying behind a standard interval scan may be unsafe.
New focal neurological deficit, spinal pain, pathological fracture or severe hypercalcaemic symptoms alongside a suspicious nodule may indicate metastatic disease and requires urgent parallel care.
Never allow an incidental result to remain unowned: failure to communicate the plan, surveillance date and responsible team is a patient-safety event.

03Method and interpretationA systematic approach to the test and its findings.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Prior imaging reviewFirst step
Why
Establish whether the lesion is new, stable or genuinely growing.
Interpretation and limitations
Compare the oldest adequate study as well as the latest one, accounting for slice thickness and technique; undocumented verbal recollection of stability is insufficient.
02
Thin-section chest CT
Why
Confirm location, attenuation, morphology, multiplicity and accurate size or volume.
Interpretation and limitations
Distinguish solid from subsolid disease, record the solid component and look for lymph nodes, emphysema, fibrosis or another diagnosis that changes management.
03
Brock risk calculation
Why
Estimate pre-test malignancy probability using validated clinical and CT features.
Interpretation and limitations
Enter radiological variables accurately and use the output within BTS eligibility and size criteria; a model informs, but does not replace, multidisciplinary judgement.
04
Interval CT volumetry
Why
Identify reproducible growth and estimate volume-doubling behaviour.
Interpretation and limitations
Use comparable technique and software where possible; apparent small changes may reflect segmentation variability, while convincing growth moves the lesion toward definitive assessment.
05
FDG PET-CT with Herder reassessment
Why
Refine malignancy probability when nodule size and pre-test risk make PET informative.
Interpretation and limitations
Recalculate risk using uptake rather than labelling a scan simply positive; infection causes false positivity, while small or low-metabolic tumours may be falsely negative.
06
Tissue sampling
Why
Obtain histology when the result will alter treatment or prevent inappropriate intervention.
Interpretation and limitations
Choose bronchoscopic, image-guided or surgical sampling from location and staging needs; a non-diagnostic sample does not equal benign disease and must return to risk review.

04Clinical next stepsHow the result changes management or prompts escalation.

01CHARACTERISEBuild a reliable starting phenotypeFirst stepA chest radiograph or CT report describes a new solitary or multiple pulmonary nodule.

1Retrieve prior imaging and clinical context, including smoking, earlier malignancy, immune status, symptoms and whether an acute infective process is plausible.
2Obtain or reconstruct appropriate thin-section CT, documenting number, attenuation, morphology, lobe, dimensions or volume and every relevant non-nodule finding.
3EscalationIdentify benign diagnostic patterns and context exceptions before applying routine surveillance; escalate masses, obstruction or urgent cancer features directly.
4Give the patient a clear written result, explanation of uncertainty, named responsible service and the next action with an expected timeframe.

02STRATIFYMatch testing to malignancy probabilityA persistent indeterminate nodule meets criteria for formal assessment rather than immediate discharge.

1For a solid nodule, apply the BTS size and Brock framework; for a subsolid nodule, confirm persistence and measure both total and solid components.
2Use comparable interval CT and volumetry when surveillance is appropriate, interpreting true growth and volume-doubling behaviour rather than visual impression alone.
3When pre-test probability and technical size justify it, perform PET-CT and incorporate uptake through Herder risk assessment while recognising biological and inflammatory limitations.
4Discuss discordant results at lung MDT, especially when a reassuring PET scan conflicts with clear growth or a high-risk morphology.

03ACTChoose observation, tissue or treatmentRisk reassessment identifies a low, intermediate or high probability lesion and patient fitness is known.

1Discharge lesions meeting benign or very-low-risk criteria, avoiding indefinite surveillance while advising how later new respiratory symptoms should be assessed.
2For surveillance, specify modality, timing, measurement method, stopping rule and who will track completion; every missed scan must generate an active recall.
3For intermediate uncertainty, select the biopsy approach most likely to give adequate tissue with acceptable risk, and predefine what a non-diagnostic result will mean.
4For high probability, assess treatment fitness and discuss resection, biopsy or non-surgical local treatment in MDT, incorporating the person's values and tolerance of uncertainty.

04INCIDENTALTriage the rest of the scanCT identifies emphysema, interstitial abnormality, coronary calcification, pleural disease or another unexpected thoracic feature.

1Separate acute actionable abnormalities from chronic risk markers and minor variants, relating each finding to symptoms and available previous imaging.
2Route suspected interstitial lung disease, bronchiectasis, pleural malignancy or airway obstruction to the relevant clinical pathway rather than hiding it inside nodule follow-up.
3Use emphysema or coronary calcification to prompt appropriate smoking, cardiovascular and symptom assessment without implying that imaging alone establishes every clinical diagnosis.
4Document which findings require no action, which need primary-care review and which remain owned by the lung service, so responsibility is unambiguous.

05Risks, monitoring and follow-upComplications, safety checks and further assessment.

Maintain a nodule register with due dates, completion status, result review and a named person responsible for chasing non-attendance or missing reports.
At each CT, compare volume and morphology with the same baseline and record whether technical differences limit confidence in apparent growth.
During surveillance, review new haemoptysis, weight loss, persistent cough or systemic illness because symptoms may require faster diagnostic work even before the next scheduled scan.
Track the solid component of subsolid lesions separately and return persistent or growing change to MDT rather than repeatedly extending observation by default.
After biopsy, monitor pneumothorax, bleeding and adequacy; a non-diagnostic report needs an explicit risk-based next step, not silent discharge.
Audit communication: the patient and primary-care clinician should know the result, residual risk, next date and route for questions or worsening symptoms.

06Special situationsVariants, exceptions and circumstances that change the usual approach.

Old imaging can be definitive

A five-minute search for an older CT may reveal years of stability or establish true growth, often contributing more than another immediate test.

Measurement has error

Very small diameter differences can reflect reconstruction or reader variability. Volumetry and consistent acquisition make growth assessment more reproducible but still require image review.

PET modifies probability

FDG uptake is neither cancer-specific nor universally present in cancer. Its value is the probability shift incorporated with pre-test risk, not a binary label.

Slow does not mean benign

Subsolid adenocarcinoma-spectrum lesions may change over years. Persistence and development or enlargement of a solid component can matter more than conventional short doubling times.

A biopsy must answer a decision

Before sampling, define how positive, specific benign and non-diagnostic outcomes would alter care. This exposes procedures unlikely to help the patient.

Ownership prevents harm

The safest surveillance schedule is ineffective if nobody checks completion. Closed-loop tracking is a clinical intervention, not an administrative extra.

07Common pitfallsFrequent interpretation and management errors.

01
Calling every rounded opacity cancer or, conversely, reassuring from a smooth margin without integrating size, growth and clinical risk.
02
Ordering surveillance before retrieving previous imaging that could establish stability or reveal a much longer growth interval.
03
Applying a solid-nodule schedule to persistent part-solid or pure ground-glass disease without tracking the solid component.
04
Treating PET-CT as a binary cancer test and overlooking false positivity from inflammation or false negativity in small and indolent lesions.
05
Discharging after a non-diagnostic biopsy as though no malignant cells means the nodule is benign.
06
Recording repeat CT advised without naming the clinician responsible for ordering, checking and communicating it.
07
Ignoring a more urgent incidental finding because the request was labelled pulmonary nodule follow-up.